Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351824 | 0.79 | TSHR (0.48) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL30945319 | 0.79 | TSHR (0.48) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL2227750 | 0.75 | TSHR (0.48) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL345760 | 0.72 | HSD17B10 (0.48) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL10688254 | 0.72 | ALDH1A1 (0.46) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL5313485 | 0.72 | ALDH1A1 (0.47) | TSHRLMNAALDH1A1TDP1PTPRC | |
| SCHEMBL1424323 | 0.72 | TSHR (0.45) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL18000477 | 0.72 | TSHR (0.47) | TSHRLMNAALDH1A1TDP1MEN1 | |
| SCHEMBL12275570 | 0.72 | TSHR (0.45) | TSHRLMNAALDH1A1TDP1ACHE | |
| SCHEMBL31536932 | 0.72 | HSD17B10 (0.48) | TSHRLMNAALDH1A1TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-7612197-B2 | Reacting a nucleophil with OH group with an electrophil to form an adduct, reacting adduct with a reagent selected from oxidizing, sulfurizing or selenizing agents to produce hydroxy protected oligonucleotide, heating to deprotect hydroxy protecting group such as 2-(2-pyridyl)aminoethoxycarbonyl | The United States of America as repesented by the Secretary of the Department of Health and Human Services (US) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | TSHR 244/4885LMNA 4804/4885ALDH1A1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.